市場調査レポート

商品コード

1447738

ワクチンアジュバント市場の評価：製品タイプ・投与経路・疾患タイプ・用途・地域別の機会および予測 (2017～2031年)

Vaccine Adjuvants Market Assessment, By Product Type, By Route of Administration, Disease Type, By Application, By Region, Opportunities and Forecast, 2017-2031F

出版日: 2024年03月11日 | 発行: Market Xcel - Markets and Data

| ページ情報: 英文 223 Pages | 納期: 3～5営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　詳細はお問い合わせください。

価格

PDF & Excel Printable (Single User License)

USD 4,500 705,420円

レポートPDFを1名の方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Corporate License)

USD 5,700 893,532円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能ですが、企業内部での利用に限定されます。ご利用に際しては、あらかじめ出版社の許諾を得る必要があります。詳細はお問合せください。印刷は可能です。Excelのデータがライセンスに含まれています。

PDF & Excel Printable (Custom Research License)

USD 8,200 1,285,432円

レポートPDFを企業の１カ国の拠点のすべての方がご利用頂けるライセンスです。レポートPDFのパスワード保護はありません。PDF内のテキスト等のコピー＆ペーストは可能です。印刷は無制限で可能です。Excelのデータがライセンスに含まれています。アナリストアワー100時間が含まれており、レポートのカスタマイズなどにご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=156.76円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のワクチンアジュバントの市場規模は、2023年の13億3,000万米ドルから、2024年から2031年の予測期間中は9.95%のCAGRで推移し、2031年には28億4,000万米ドルの規模に成長すると予測されています。

世界のワクチンアジュバント市場は、いくつかの重要な要因によって大きな成長を遂げています。感染症の流行がワクチン需要の増加につながり、市場拡大を後押ししています。バイオテクノロジーの技術的進歩も市場を前進させる上で重要な役割を果たしています。さらに、R&D活動に対する政府の資金援助や投資の増加がこの成長軌道に拍車をかけています。主要参入企業間の戦略的提携や協力も市場拡大に寄与する重要な要因となっています。

ワクチン、バイオ医薬品、治療薬に対する需要の高まり

これまで以上に多くのワクチン、バイオ医薬品、治療薬が必要とされています。COVID-19によって、ワクチンは現在も将来もさらに不可欠なものとなっています。ワクチンアジュバントはワクチンに不可欠な成分であり、ワクチンの使用が増えれば、結果的にワクチンアジュバントの需要も高まることになります。医療分野では、バイオ医薬品、遺伝子治療薬、細胞治療薬がますます普及しています。人口の増加、疾病の拡大、パンデミックの脅威、COVID後の対応策、人々の意識の高まりなどの要因が、今後数年間のワクチンアジュバント需要を牽引しています。

感染症の流行拡大

感染症の流行は、気候変動、急速な都市化、土地利用パターンの変化など、いくつかの要因によって増加しています。これらの要因は、新しい疾病の出現、古い疾病の再出現、既存の疾病の蔓延につながります。医療の向上や世界的な旅行といった技術的な変化も感染症の蔓延に寄与しています。さらに、人口増加や移民などの人口動態の変化も、疾病の発生リスクを高める可能性があります。感染症の流行が増加するにつれ、ワクチンの需要も高まります。世界保健機関 (WHO) は、世界の年間死亡者数の約3分の1が感染症によるものと推定しており、急性呼吸器感染症、消化器感染症、結核、マラリアが世界の疾病と死亡の大半を引き起こしています。

炭水化物アジュバントが急成長

炭水化物ベースのアジュバントはワクチン開発においてますます人気が高まっています。これらは安全で身体に適合すると考えられており、免疫反応を誘発し制御することができます。これらのアジュバントは、サブユニットワクチンと併用することで、身体の免疫反応を高め、ワクチンをより効果的にするのに役立ちます。天然および合成の炭水化物がアジュバントとして臨床試験でテストされ、ヒト用ワクチンへの使用が承認されたものもあります。炭水化物アジュバントには、体への適合性が高い、忍容性が高い、安全性が高いなど、いくつかの利点があります。これらの点から、ワクチンのアジュバントとして有望視されています。

当レポートでは、世界のワクチンアジュバントの市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

市場規模・予測
製品タイプ別
- ミネラル塩アジュバント
- 張力活性アジュバント
- アジュバントエマルジョン
- リポソームアジュバント
- 炭水化物アジュバント
- 細菌由来アジュバント
- ウイルス様粒子 (VLP)
- その他
投与経路別
- 皮下
- 筋肉内
疾患タイプ別
- 感染症
- 癌
用途別
- 研究
- 商用
地域別
- 北米
- 欧州
- 南米
- アジア太平洋
- 中東・アフリカ
企業別の市場シェア

第5章世界のワクチンアジュバント市場の展望：地域別

北米
欧州
南米
アジア太平洋
中東・アフリカ

第6章市場マッピング

製品タイプ別
投与経路別
疾患タイプ別
用途別
地域別

第7章マクロ環境・産業構造

需給分析
輸出入分析
バリューチェーン分析
PESTEL分析
ポーターのファイブフォース分析

第8章市場力学

成長促進要因
成長阻害要因 (課題・抑制要因)

第9章規制の枠組みとイノベーション

特許の情勢
規制当局の承認
イノベーション/新興技術

第10章主要企業の情勢

市場リーダー上位5社の競合マトリックス
市場リーダー上位5社の市場収益分析
M&A・ジョイントベンチャー (該当する場合)
SWOT分析 (主要企業)

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

Brenntag Biosector A/S
OZ Biosciences.
Agenus, Inc.
Spectrum Pharmaceuticals, Inc.
SEPPIC, Inc.
Novavax, Inc.
MPV Technologies
CSL Corporate
Avanti Polar Lipids, Inc.
Invivogen

第14章戦略的提言

第15章当社について・免責事項

図表

List of Tables

Table 1. Pricing Analysis of Products from Key Players
Table 2. Competition Matrix of Top 5 Market Leaders
Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

Figure 1.Global Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 2.Global Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 3.Global Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 4.Global Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 5.Global Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 6.Global Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 7.Global Vaccine Adjuvants Market Share (%), By Region, 2017-2031F
Figure 8.North America Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 9.North America Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 10.North America Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 11.North America Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 12.North America Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 13.North America Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 14.North America Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
Figure 15.United States Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 16.United States Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 17.United States Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 18.United States Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 19.United States Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 20.United States Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 21.Canada Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 22.Canada Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 23.Canada Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 24.Canada Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 25.Canada Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 26.Canada Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 27.Mexico Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 28.Mexico Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 29.Mexico Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 30.Mexico Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 31.Mexico Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 32.Mexico Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 33.Europe Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 34.Europe Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 35.Europe Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 36.Europe Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 37.Europe Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 38.Europe Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 39.Europe Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
Figure 40.Germany Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 41.Germany Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 42.Germany Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 43.Germany Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 44.Germany Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 45.Germany Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 46.France Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 47.France Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 48.France Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 49.France Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 50.France Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 51.France Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 52.Italy Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 53.Italy Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 54.Italy Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 55.Italy Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 56.Italy Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 57.Italy Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 58.United Kingdom Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 59.United Kingdom Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 60.United Kingdom Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 61.United Kingdom Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 62.United Kingdom Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 63.United Kingdom Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 64.Russia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 65.Russia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 66.Russia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 67.Russia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 68.Russia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 69.Russia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 70.Netherlands Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 71.Netherlands Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 72.Netherlands Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 73.Netherlands Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 74.Netherlands Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 75.Netherlands Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 76.Spain Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 77.Spain Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 78.Spain Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 79.Spain Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 80.Spain Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 81.Spain Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 82.Turkey Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 83.Turkey Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 84.Turkey Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 85.Turkey Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 86.Turkey Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 87.Turkey Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 88.Poland Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 89.Poland Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 90.Poland Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 91.Poland Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 92.Poland Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 93.Poland Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 94.South America Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 95.South America Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 96.South America Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 97.South America Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 98.South America Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 99.South America Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 100.South America Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
Figure 101.Brazil Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 102.Brazil Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 103.Brazil Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 104.Brazil Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 105.Brazil Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 106.Brazil Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 107.Argentina Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 108.Argentina Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 109.Argentina Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 110.Argentina Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 111.Argentina Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 112.Argentina Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 113.Asia-Pacific Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 114.Asia-Pacific Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 115.Asia-Pacific Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 116.Asia-Pacific Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 117.Asia-Pacific Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 118.Asia-Pacific Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 119.Asia-Pacific Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
Figure 120.India Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 121.India Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 122.India Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 123.India Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 124.India Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 125.India Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 126.China Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 127.China Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 128.China Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 129.China Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 130.China Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 131.China Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 132.Japan Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 133.Japan Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 134.Japan Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 135.Japan Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 136.Japan Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 137.Japan Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 138.Australia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 139.Australia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 140.Australia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 141.Australia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 142.Australia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 143.Australia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 144.Vietnam Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 145.Vietnam Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 146.Vietnam Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 147.Vietnam Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 148.Vietnam Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 149.Vietnam Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 150.South Korea Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 151.South Korea Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 152.South Korea Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 153.South Korea Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 154.South Korea Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 155.South Korea Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 156.Indonesia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 157.Indonesia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 158.Indonesia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 159.Indonesia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 160.Indonesia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 161.Indonesia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 162.Philippines Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 163.Philippines Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 164.Philippines Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 165.Philippines Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 166.Philippines Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 167.Philippines Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 168.Middle East & Africa Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 169.Middle East & Africa Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 170.Middle East & Africa Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 171.Middle East & Africa Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 172.Middle East & Africa Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 173.Middle East & Africa Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 174.Middle East & Africa Vaccine Adjuvants Market Share (%), By Country, 2017-2031F
Figure 175.Saudi Arabia Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 176.Saudi Arabia Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 177.Saudi Arabia Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 178.Saudi Arabia Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 179.Saudi Arabia Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 180.Saudi Arabia Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 181.UAE Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 182.UAE Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 183.UAE Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 184.UAE Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 185.UAE Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 186.UAE Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 187.South Africa Vaccine Adjuvants Market, By Value, In USD Billion, 2017-2031F
Figure 188.South Africa Vaccine Adjuvants Market, By Volume, In Million Units, 2017-2031F
Figure 189.South Africa Vaccine Adjuvants Market Share (%), By Product Type, 2017-2031F
Figure 190.South Africa Vaccine Adjuvants Market Share (%), By Route of Administration, 2017-2031F
Figure 191.South Africa Vaccine Adjuvants Market Share (%), By Disease Type, 2017-2031F
Figure 192.South Africa Vaccine Adjuvants Market Share (%), By Application, 2017-2031F
Figure 193.By Product Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 194.By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 195.By Disease Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 196.By Application Map-Market Size (USD Billion) & Growth Rate (%), 2023
Figure 197.By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Product Code: MX11145

Global vaccine adjuvants market is projected to witness a CAGR of 9.95% during the forecast period 2024-2031F, growing from USD 1.33 billion in 2023 to USD 2.84 billion in 2031. The global vaccine adjuvants market is witnessing substantial growth driven by several key factors. The increasing prevalence of infectious diseases has led to a rising demand for vaccines, propelling market expansion. Technological advancements in biotechnology are also playing a significant role in driving the market forward. Moreover, increased government funding and investments in research and development activities are fueling this growth trajectory. Strategic collaborations and partnerships among key industry players are also acting as crucial factors contributing to the market's expansion. Vaccine adjuvants enhance immunogenicity, leading to more effective vaccines with reduced antigen content, crucial for mass vaccination campaigns. However, challenges like side effects and toxicity associated with some adjuvants, particularly aluminum adjuvants, which can cause local injection site reactions and allergic responses hinder the market. Additionally, the concern for public health and safety may limit the adoption of certain adjuvants if they pose risks or potential harm to individuals receiving them.

In October 2023, after careful evaluation, the World Health Organization (WHO) approved the use of the R21/Matrix-M malaria vaccine. Developed by the University of Oxford, the Serum Institute of India, and leveraging Novavax's adjuvant technology, the vaccine has met strict standards for safety, quality, and effectiveness. Experts from the WHO's independent advisory groups, SAGE and MPAG, conducted a thorough review and found that the vaccine is effective and safe. Clinical trials in various regions with different malaria transmission rates have demonstrated its efficacy.

Growing Demand for Vaccines, Biopharmaceuticals, and Therapy Products

More vaccines, biopharmaceuticals, and therapies are needed than ever before. COVID-19 has made vaccines even more essential, both now and in the future. Vaccine adjuvants are essential components of vaccines and increasing the use of vaccines will ultimately enhance the demand for vaccine adjuvants. In the medical sector, biopharmaceuticals, gene therapies, and cell therapies are becoming more and more popular. Factors, such as population growth, escalating disease prevalence, pandemic threats, post-COVID readiness measures, and heightened public awareness, are driving the demand for vaccine adjuvants in the upcoming years.

As per the WHO report published in May 2023, between the years 2019 and 2021, a significant increase in the consumption of vaccines has been observed. The adult vaccines segment grew by 15%, pediatric vaccines registered a growth of 8%, and vaccines used for adolescents registered a growth of 7%. This data does not consider COVID-19 vaccines, but still, a significant change in demand can be seen.

Growing Prevalence of Infectious Diseases

The prevalence of infectious diseases is increasing due to several factors, including climate change, rapid urbanization, and changes in land-use patterns. These factors contribute to the emergence of new diseases, the re-emergence of old diseases, and the spread of existing diseases. Technological changes, such as improved health care and global travel, also contribute to the spread of infectious diseases. Additionally, demographic changes, such as population growth and migration, can increase the risk of disease emergence. As the prevalence of infectious diseases increases, the demand for vaccines rises, subsequently enhancing the market demand for vaccine adjuvants as they are essential components of the finished vaccines. The World Health Organization estimates that approximately one-third of annual deaths worldwide are attributed to infectious diseases, with acute respiratory tract infections, gastrointestinal infections, tuberculosis, and malaria causing most of the illnesses and mortality worldwide.

For instance, as per the data published by Worldometers, over 703 million COVID-19 cases were reported till February 2024, along with 69 million deaths reported. COVID-19 has been the most contagious and lethal infectious disease in recent times.

Carbohydrate-based Adjuvants are Fastest Growing

Carbohydrate-based adjuvants are becoming increasingly popular in vaccine development. They are considered safe and compatible with the body, and they can trigger and control immune responses. These adjuvants help make vaccines more effective by boosting the body's immune response when used with subunit vaccines. Natural and synthetic carbohydrates have been tested as adjuvants in clinical trials, and some have been approved for use in human vaccines. Carbohydrate-based adjuvants offer several advantages, including being highly compatible with the body, well-tolerated, and having a good safety record. These factors make them promising candidates for use as adjuvants in vaccines.

Infectious Disease to be the Leading Disease Type

The infectious disease segment is expected to be the leading disease type for utilizing vaccines for treatment purposes. A variety of vaccines are available in the market for infectious diseases like hepatitis, polio, tetanus, and influenza. Vaccines are highly effective in infectious diseases because they provide long-lasting immunity, protect against severe illness and death, and reduce the spread of the disease within a population. Vaccines work by imitating an infection, engaging the body's natural immune response, and providing protection without the dangers of a full-blown infection. Vaccines are more effective in infectious diseases because they target specific pathogens, and their development is based on the characteristics of the pathogen, such as antigenic stability, serotype, and the presence of diagnostic tests or clinical criteria for measuring disease burden.

In May 2023, GSK announced the US Food and Drug Administration's approval for its Arexvy (respiratory syncytial virus vaccine, adjuvanted) meant for the prevention of lower respiratory tract disease (LRTD) caused due to respiratory syncytial virus (RSV) in patients of 60 years of age and older. Arexvy is the world's first RSV vaccine for elders to be approved.

North America to be the Dominating Region

North America's leadership in the vaccine adjuvant market stems from several key reasons. Governments are investing heavily in research, and companies within the industry are partnering to achieve breakthroughs. The region's healthcare system is well-developed, with a focus on preventive care. This encourages the use of adjuvanted vaccines, which make vaccines more effective and are thoroughly tested before being approved. This reflects the region's commitment to preventive healthcare measures. Additionally, the region's strong regulatory framework ensures the safety and efficacy of adjuvanted vaccines, further boosting market confidence. US FDA considers vaccine adjuvant as a part of the vaccine and not as a separate entity, thus separate approval for vaccine adjuvant is not required.

Future Market Scenario

The future of vaccine adjuvants is expected to focus on the development of new, more effective, and safer adjuvants. Research is being conducted to create adjuvants that can enhance the immune response to vaccines, particularly for subunit vaccines, which are often less effective at generating a robust immune response. New adjuvants are being developed from natural resources and synthetic components, to improve safety and protective efficacy. Technologies, such as nanotechnologies and molecular biology, are being used to improve vaccine efficacy, and adjuvants are being designed to stimulate immune responses in a more targeted manner. Additionally, systems vaccinology approaches are being used to assess and characterize new adjuvant systems, which may help in the rational design of vaccines in the future.

Key Players Landscape and Outlook

Brenntag Biosector A/S, OZ Biosciences, Agenus, Inc., Spectrum Pharmaceuticals, Inc., SEPPIC, Inc., Novavax, Inc., and MPV Technologies are some of the key players in the vaccine adjuvants market. These companies are actively involved in the production and advancement of vaccine adjuvants, contributing to the growth and innovation within the industry. The market is competitive, with a focus on enhancing vaccine efficacy, reducing production costs, and developing safer and more effective vaccines through ongoing advancements in technology and formulations.

In February 2024, DTRA's JSTO awarded a USD 31 million, 5-year contract to Ginkgo Bioworks and SaponiQx through the MCDC program to develop cutting-edge vaccine adjuvants. Ginkgo, specializing in cell programming and biosecurity, and SaponiQx, with its innovative adjuvant platform, have been collaborating on this project since 2021.

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Vaccine Adjuvants Market Outlook, 2017-2031F

4.1.Market Size & Forecast
- 4.1.1. By Value
- 4.1.2. By Volume
4.2.By Product Type
- 4.2.1.Mineral Salt-based Adjuvant
- 4.2.2.Tensoactive Adjuvants
- 4.2.3.Adjuvant Emulsions
- 4.2.4.Liposome Adjuvants
- 4.2.5.Carbohydrate Adjuvants
- 4.2.6.Bacteria-derived Adjuvants
- 4.2.7.Virus-like Particles (VLP)
- 4.2.8.Others
4.3.By Route of Administration
- 4.3.1.Subcutaneous
- 4.3.2.Intramuscular
4.4.Disease Type
- 4.4.1.Infectious Diseases
- 4.4.2.Cancer
4.5.By Application
- 4.5.1.Research Applications
- 4.5.2.Commercial Applications
4.6.By Region
- 4.6.1.North America
- 4.6.2.Europe
- 4.6.3.Asia-Pacific
- 4.6.4.South America
- 4.6.5.Middle East and Africa
4.7.By Company Market Share (%), 2023

5.Global Vaccine Adjuvants Market Outlook, By Region, 2017-2031F

5.1.North America*
- 5.1.1.Market Size & Forecast
  - 5.1.1.1.By Value
  - 5.1.1.2.By Volume
- 5.1.2.By Product Type
  - 5.1.2.1.Mineral Salt-based Adjuvant
  - 5.1.2.2.Tensoactive Adjuvants
  - 5.1.2.3.Adjuvant Emulsions
  - 5.1.2.4.Liposome Adjuvants
  - 5.1.2.5.Carbohydrate Adjuvants
  - 5.1.2.6.Bacteria-derived Adjuvants
  - 5.1.2.7.Virus-like Particles (VLP)
  - 5.1.2.8.Others
- 5.1.3.By Route of Administration
  - 5.1.3.1.Subcutaneous
  - 5.1.3.2.Intramuscular
- 5.1.4.Disease Type
  - 5.1.4.1.Infectious Diseases
  - 5.1.4.2.Cancer
- 5.1.5.By Application
  - 5.1.5.1.Research Applications
  - 5.1.5.2.Commercial Applications
- 5.1.6.United States*
  - 5.1.6.1.Market Size & Forecast
  - 5.1.6.1.1.By Value
  - 5.1.6.1.2.By Volume
  - 5.1.6.2.By Product Type
  - 5.1.6.2.1.Mineral Salt-based Adjuvant
  - 5.1.6.2.2.Tensoactive Adjuvants
  - 5.1.6.2.3.Adjuvant Emulsions
  - 5.1.6.2.4.Liposome Adjuvants
  - 5.1.6.2.5.Carbohydrate Adjuvants
  - 5.1.6.2.6.Bacteria-derived Adjuvants
  - 5.1.6.2.7.Virus-like Particles (VLP)
  - 5.1.6.2.8.Others
  - 5.1.6.3.By Route of Administration
  - 5.1.6.3.1.Subcutaneous
  - 5.1.6.3.2.Intramuscular
  - 5.1.6.4.Disease Type
  - 5.1.6.4.1.Infectious Diseases
  - 5.1.6.4.2.Cancer
  - 5.1.6.5.By Application
  - 5.1.6.5.1.Research Applications
  - 5.1.6.5.2.Commercial Applications
- 5.1.7.Canada
- 5.1.8.Mexico

All segments will be provided for all regions and countries covered

5.2.Europe
- 5.2.1.Germany
- 5.2.2.France
- 5.2.3.Italy
- 5.2.4.United Kingdom
- 5.2.5.Russia
- 5.2.6.Netherlands
- 5.2.7.Spain
- 5.2.8.Turkey
- 5.2.9.Poland
5.3.Asia-Pacific
- 5.3.1.India
- 5.3.2.China
- 5.3.3.Japan
- 5.3.4.Australia
- 5.3.5.Vietnam
- 5.3.6.South Korea
- 5.3.7.Indonesia
- 5.3.8.Philippines
5.4.South America
- 5.4.1.Brazil
- 5.4.2.Argentina
5.5.Middle East & Africa
- 5.5.1.Saudi Arabia
- 5.5.2.UAE
- 5.5.3.South Africa

6.Market Mapping, 2023

6.1.By Product Type
6.2.By Route of Administration
6.3.By Disease Type
6.4.By Application
6.5.By Region

7.Macro Environment and Industry Structure

7.1.Demand Supply Analysis
7.2.Import Export Analysis
7.3.Value Chain Analysis
7.4.PESTEL Analysis
- 7.4.1.Political Factors
- 7.4.2.Economic System
- 7.4.3.Social Implications
- 7.4.4.Technological Advancements
- 7.4.5.Environmental Impacts
- 7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)
7.5.Porter's Five Forces Analysis
- 7.4.7.Supplier Power
- 7.4.8.Buyer Power
- 7.4.9.Substitution Threat
- 7.4.10.Threat from New Entrant
- 7.4.11.Competitive Rivalry

8.Market Dynamics

8.1.Growth Drivers
8.2.Growth Inhibitors (Challenges and Restraints)

9.Regulatory Framework and Innovation

9.1.Patent Landscape
9.2.Regulatory Approvals
9.3.Innovations/Emerging Technologies

10.Key Players Landscape

10.1.Competition Matrix of Top Five Market Leaders
10.2.Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
10.3.Mergers and Acquisitions/Joint Ventures (If Applicable)
10.4.SWOT Analysis (For Five Market Players)

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

13.1.Brenntag Biosector A/S
- 13.1.1.Company Details
- 13.1.2.Key Management Personnel
- 13.1.3.Products & Services
- 13.1.4.Financials (As reported)
- 13.1.5.Key Market Focus & Geographical Presence
- 13.1.6.Recent Developments
13.2.OZ Biosciences.
13.3.Agenus, Inc.
13.4.Spectrum Pharmaceuticals, Inc.
13.5.SEPPIC, Inc.
13.6.Novavax, Inc.
13.7.MPV Technologies
13.8.CSL Corporate
13.9.Avanti Polar Lipids, Inc.
13.10.Invivogen

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

ワクチンアジュバント市場の評価：製品タイプ・投与経路・疾患タイプ・用途・地域別の機会および予測 (2017～2031年)

Vaccine Adjuvants Market Assessment, By Product Type, By Route of Administration, Disease Type, By Application, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のワクチンアジュバント市場の展望

第5章世界のワクチンアジュバント市場の展望：地域別

第6章市場マッピング

第7章マクロ環境・産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Vaccine Adjuvants Market Outlook, 2017-2031F

5.Global Vaccine Adjuvants Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

ワクチンアジュバント市場の評価：製品タイプ・投与経路・疾患タイプ・用途・地域別の機会および予測 (2017～2031年)

Vaccine Adjuvants Market Assessment, By Product Type, By Route of Administration, Disease Type, By Application, By Region, Opportunities and Forecast, 2017-2031F

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界のワクチンアジュバント市場の展望

第5章 世界のワクチンアジュバント市場の展望：地域別

第6章 市場マッピング

第7章 マクロ環境・産業構造

第8章 市場力学

第9章 規制の枠組みとイノベーション

第10章 主要企業の情勢

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

List of Figures

Table of Contents

1.Research Methodology

2.Project Scope & Definitions

3.Executive Summary

4.Global Vaccine Adjuvants Market Outlook, 2017-2031F

5.Global Vaccine Adjuvants Market Outlook, By Region, 2017-2031F

6.Market Mapping, 2023

7.Macro Environment and Industry Structure

8.Market Dynamics

9.Regulatory Framework and Innovation

10.Key Players Landscape

11.Pricing Analysis

12.Case Studies

13.Key Players Outlook

14.Strategic Recommendations

15.About Us & Disclaimer

第1章調査手法

第2章プロジェクトの範囲と定義

第3章エグゼクティブサマリー

第4章世界のワクチンアジュバント市場の展望

第5章世界のワクチンアジュバント市場の展望：地域別

第6章市場マッピング

第7章マクロ環境・産業構造

第8章市場力学

第9章規制の枠組みとイノベーション

第10章主要企業の情勢

第11章価格分析

第12章ケーススタディ

第13章主要企業の見通し

第14章戦略的提言

第15章当社について・免責事項